To effectively respond to emerging diseases, the ability to rapidly produce vaccines or therapeutic antibodies in the face of an outbreak such as pandemic influenza is critical. Medicago has developed the Proficia™ technology, a proprietary alternative to current egg-based and cell production systems. Using whole living plants as hosts, our Proficia™ technology is a rapid, flexible, high yielding and robust vaccine and antibody production system. A major advantage of this system based on transient protein expression in plant leaves is unmatched speed. Vaccine production can be initiated within less than three weeks from the identification of the genetic sequence from a pandemic or seasonal influenza strain.